Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization

Cancer Journal

Volumn 7, Issue 5, 2001, Pages 395-403

  Liu, Howard L ^a,b   Gandour Edward, Regina ^a,c,d   Lara Jr , Primo N ^a,c   De Vere White, Ralph ^a,c   Lasalle, Janine M ^a,c  

^a University of California ^*

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

FISH; HER 2 neu; Immunohistochemistry; Prostate cancer

Indexed keywords

MONOCLONAL ANTIBODY; TRASTUZUMAB;

ANEUPLOIDY; ARTICLE; CANCER GROWTH; CHROMOSOME 17; CLINICAL ARTICLE; COMPARATIVE STUDY; DIPLOIDY; DNA PROBE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE IDENTIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; METASTASIS; ONCOGENE NEU; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; STAINING; ADENOCARCINOMA; GENETICS; NUCLEIC ACID AMPLIFICATION; PROSTATE TUMOR; PROTO ONCOGENE;

ADENOCARCINOMA; ANEUPLOIDY; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PROSTATIC NEOPLASMS;

EID: 0035464538     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Schechter AL, Hung MC, Vaidyanathan L et al. The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 1985;229:976-978.
2. Zhau HY, Zhou J, Symmans WF et al. Transfected neu oncogene induces human prostate cancer metastasis. Prostate 1996;28:73-83.
3. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712.
4. Press MF, Bernstein L, Thomas PA et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997;15:2894-2904.
5. Ross JS, Nazeer T, Church K et al. Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis. Cancer 1993;72:3020-3028.
6. Saffari B, Jones LA, el-Naggar A et al. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival. Cancer Res 1995;55:5693-5698.
7. Ranzani GN, Pellegata NS, Previdere C et al. Heterogeneous protooncogene amplification correlates with tumor progression and presence of metastases in gastric cancer patients. Cancer Res 1990;50:7811-7814.
8. Press ME Pike MC, Hung G et al. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res 1994;54:5675-5682.
9. Zhau HE, Zhang X, von Eschenbach AC et al. Amplification and expression of the c-erb B-2/neu proto-oncogene in human bladder cancer. Mol Carcinog 1990;3:254-257.
10. Moriyama M, Akiyama T, Yamamoto T et al. Expression of c-erbB-2 gene product in urinary bladder cancer. J Urol 1991;145:423-427.
11. Ross JS, Sheehan CE, Hayner-Buchan AM et al. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer 1997;79:2162-2170.
12. Morote J, de Torres I, Caceres C et al. Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastatic prostate cancer. Int J Cancer 1999;84:421-425.
13. Press MF, Hung G, Godolphin W et al. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54:2771-2777.
14. Jacobs TW, Gown AM, Yaziji H et al. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 1999;17:1974.
15. Pauletti G, Godolphin W, Press MF et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996;13:63-72.
16. Pauletti G, Dandekar S, Rang H et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: as direct comparison of fluorescence in situ hybridization and immuno histochemistry. J Clin Oncol 2000;18:3651-3664.
17. Ciocca DR, Fujimura FK, Tandon AK et al. Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J Natl Cancer Inst 1992;84:1279-1281.
18. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998;16:413-428.
19. Szollosi J, Balazs M, Feuerstein BG et al. ERBB-2 (HER2/neu) gene copy number, p185-HER2 overexpression, and intra tumor heterogeneity in human breast cancer. Cancer Res 1995;55:5400-5407.
20. Czerniak B, Herz F, Wersto RP, Koss LG. Asymmetric distribution of oncogene products at mitosis. Proc Natl Acad Sci USA 1992;89:4860-4863.
21. Bacus SS, Bacus JW, Slamon DJ et al. HER-2/neu oncogene expression and DNA ploidy analysis in breast cancer. Arch Pathol Lab Med 1990;114:164-169.
22. Mark HF, Feldman D, Das S et al. Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer. Exp Mol Pathol 1999;66:170-178.
23. Bubendorf L, Kononen J, Koivisto P et al. Survey of gene amplifications during prostate cancer progression by high-throughput fluorescence in situ hybridization on tissue microarray. Cancer Res 1999;59:803-806.
24. Mass RD, Sanders C, Kasain C et al. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin™ pivotal trials [abstract]. Presented at the American Society of Clinical Oncology, April 2000, New Orleans, LA.